Abstract:Background: Cancer cachexia is a debilitating syndrome associated with marked body loss because of muscular atrophy and fat loss. There are several mechanisms contributing to the pathogenesis of cachexia. The presence of the tumor releases cytokines from inflammatory and immune cells, which play a significant role in activating and deactivating certain pathways associated with protein, carbohydrate, and lipid metabolism. This review focuses on various cascades involving an imbalance between protein synthesis and degradation in the skeletal muscles. Objectives: This study aimed to elucidate the mechanisms involved in skeletal muscle wasting phenomenon over the last few years. Methods: This article briefly overviews different pathways responsible for muscle atrophy in cancer cachexia. Studies published up to April 2023 were included. Important findings and study contributions were chosen and compiled using several databases including PubMed, Google Scholar, Science Direct, and ClinicalTrials.gov using relevant keywords. Results: Cancer cachexia is a complex disease involving multiple factors resulting in atrophy of skeletal muscles. Systemic inflammation, altered energy balance and carbohydrate metabolism, altered lipid and protein metabolism, and adipose tissue browning are some of the major culprits in cancer cachexia. Increased protein degradation and decreased protein synthesis lead to muscle atrophy. Changes in signaling pathway like ubiquitin-proteasome, autophagy, mTOR, AMPK, and IGF-1 also lead to muscle wasting. Physical exercise, nutritional supplementation, steroids, myostatin inhibitors, and interventions targeting on inflammation have been investigated to treat cancer cachexia. Some therapy showed positive results in preclinical and clinical settings, although more research on the efficacy and safety of the treatment should be done. Conclusion: Muscle atrophy in cancer cachexia is the result of multiple complex mechanisms; as a result, a lot more research has been done to describe the pathophysiology of the disease. Targeted therapy and multimodal interventions can improve clinical outcomes for patients.

Spontaneous bacterial peritonitis and bacteremia due to Leuconostoc species in a patient with end-stage liver disease: a case report.

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Molecular Mechanisms of Cachexia: A Review

Understanding cachexia as a cancer metabolism syndrome

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

Cancer cachexia：pathogenic mechanisms and therapeutic perspectives

Central neural mechanisms of cancer cachexia

Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

Cancer cachexia: Pathophysiology and association with cancer-related pain

Understanding cachexia and its impact on lung cancer and beyond

Pancreatic Cancer Cachexia: The Role of Nutritional Interventions

Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia

Mechanisms of Ovarian Cancer-Associated Cachexia

Metronidazole treatment of women with a positive fetal fibronectin test result.

Targeting cancer cachexia: Molecular mechanisms and clinical study

Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting

Immunoregulation in cancer-associated cachexia

Developing and assessing teamwork skills in a multi-disciplinary course

Cancer cachexia: molecular mechanisms and treatment strategies

Molecular mechanisms of cancer cachexia. Role of exercise training

A comprehensive review of animal models for cancer cachexia: Implications for translational research